Compare REFR & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFR | IRIX |
|---|---|---|
| Founded | 1965 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 18.2M |
| IPO Year | 1995 | 1996 |
| Metric | REFR | IRIX |
|---|---|---|
| Price | $0.64 | $1.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.4K | ★ 63.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | $1,488,642.00 | ★ $41,593,000.00 |
| Revenue This Year | N/A | $3.07 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.87 |
| 52 Week High | $2.70 | $1.65 |
| Indicator | REFR | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 23.16 | 57.41 |
| Support Level | N/A | $0.99 |
| Resistance Level | $0.83 | $1.21 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 67.74 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.